Dr. Clarissa Baldotto

Dr. Clarissa Baldotto

Oncology


Dr. Clarissa Baldotta obtained a Masters in Cancer Studies through the Instituto Nacional de Câncer and a Doctorate in Medical Sciences through the Instituto D'Or de Pesquisa e Ensino. She is licensed to practice with the CRM-RJ under license # 705314.

She is the current president of the Grupo Brasileiro de Oncologia Torácica (GBOT) and Director of the Sociedade Brasileira de Oncologia Clínica (SBOC). She is also a member of the American Society of Clinical Oncology (ASCO) and International Association for the Study of Lung Cancer(IASLC).

Currently, she is a Clinical Oncologist and Director of Integrated Care in the Oncology Department at D'Or in Rio de Janeiro.


Specialties / Areas of Interest

  • Oncology
  • Lung cancer 

Academic Background

  • Doctorate in Medical Sciences from the Instituto D’Or de Pesquisa e Ensino - IDOR
  • Masters in Clinical Cancer Studies from the Instituto Nacional do Câncer - INCA
  • Medicine degree from the Universidade Federal Fluminense - UFF

Affiliations / Clinical Experience

  • President of the Grupo Brasileiro de Oncologia Torácica (GBOT)
  • Director of Integrated Care at  Oncologia D’Or of Rio de Janeiro
  • Director of the Sociedade Brasileira de Oncologia Clínica (SBOC)
  • Coordinator of the Cancer Medical Residency Program at  IDOR in Rio de Janeiro
  • Member of the American Society of Clinical Oncology (ASCO)
  • Member of the International Association for the Study of Lung Cancer (IASLC)

Publications / Projects / Awards

  • Prêmio International Development and Education Award - em 2010 - pela ASCO (American Society of clinical Oncology)
  • Araujo LH, Baldotto CS, Monteiro MR, Aguiar PN, Andrade MC, Longo CL, Batista M, Lima R, Azevedo D, Carvalho N, Andrade P, Zukin M, Teich N. Patient-centered outcomes in non-small-cell lung cancer: a real-world perspective. Future Oncol. 2021 May;17(14):1721-1733. Epub 2021 Feb 25. PMID: 33626916. Link https://www.futuremedicine.com/doi/10.2217/fon-2020-0991
  • Mak, K. S., Bommel, A. C. M. V., Stowell, C., Abrahm, J. L., Baker, M., Baldotto, C., Baldwin, D. R., Borthwick, D., Carbone, D. P., Chen, A. B., Haswell, T., Koczywas, M., Kozower, B. D., Mehran, R. J., Schramel, F. M., Senan, S., Stirling, R. G., Meerbeeck, J. P. van, Wouters, M. W. J. M., & Peake, M. D. (2015). Defining a Standard Set of Patient Centered Outcomes for Patients With Lung Cancer. International Journal of Radiation Oncology, Biology, Physics, 93(3), E403. Link https://linkinghub.elsevier.com/retrieve/pii/S0360301615023068
  • Zukin M, Barrios CH, Pereira JR, Ribeiro Rde A, Beato CA, do Nascimento YN, Murad A, Franke FA, Precivale M, Araujo LH, Baldotto CS, Vieira FM, Small IA, Ferreira CG, Lilenbaum RC. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol. 2013 Aug 10;31(23):2849-53. Epub 2013 Jun 17. PMID: 23775961. Link https://ascopubs.org/doi/10.1200/JCO.2012.48.1911
  • Ramlau R, Gorbunova V, Ciuleanu TE, Novello S, Ozguroglu M, Goksel T, Baldotto C, Bennouna J, Shepherd FA, Le-Guennec S, Rey A, Miller V, Thatcher N, Scagliotti G. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. J Clin Oncol. 2012 Oct 10;30(29):3640-7. Epub 2012 Sep 10. PMID: 22965962. Link https://ascopubs.org/doi/10.1200/JCO.2012.42.6932
  • Baldotto CS, Cronemberger EH, de Biasi P, Zamboni M, Sousa A, Zukin M, Small IA, Ferreira CG. Palliative care in poor-performance status small cell lung cancer patients: is there a mandatory role for chemotherapy? Support Care Cancer. 2012 Nov;20(11):2721-7. Epub 2012 Feb 10. PMID: 22322592. Link https://link.springer.com/article/10.1007/s00520-012-1392-0